https://www.selleckchem.com/products/anlotinib-al3818.html BACKGROUND Cancer is the second leading cause of mortality worldwide. Despite of several advances made in the treatment strategies, cure for cancer remains still a challenge. Currently used treatment modalities pose several side effects and remain ineffective in the later stages. Thiazolidinediones (TZDs) have been shown to possess anti-cancer activity in several in vitro models. OBJECTIVES The objectives of this study were to assess the effect of novel synthesized thiazolidinedione derivatives on three selected cancer cell lines viz., human breast adenocarcinoma cell line (MCF-7), lung adenocarcinoma (A549) and colorectal carcinoma (HT29).This study also aimed to evaluate the anti-inflammatory and DNA binding activity of the synthesized derivatives. METHODS The synthesized thiazolidinedione derivatives were screened for their in vitro anticancer activity on human breast adenocarcinoma cell line (MCF-7), lung adenocarcinoma (A549) and colorectal carcinoma (HT29) using Methyl Thaizolyl Tetrazolium (MTT) Assay.affinity of the test compounds was also found. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.PURPOSE Tumor Necrosis Factor Receptor 1 (TNFR1) and integrin αvβ3 receptor are overexpressed in breast cancer. We hypothesized that a peptide ligand recognizing both receptors in a single receptor-binding probe would be advantageous. Here, we developed a novel 18F-labeled fusion peptide probe [18F]-NOTA-Gly3-E(2PEG4-RGD-WH701) targeting dual receptors (TNFR1 and αvβ3) and evaluated the diagnostic efficacy of this radioactive probe in both MDA-MB-231 and MCF-7 xenograft models in mice. METHODS The NOTA-conjugated RGD-WH701 analog was radiolabeled with 18F using NOTA-AlF chelation method. We used two PEG4 molecules and glutamic acid (Glu) to covalently link c(RGDyK) with WH701. Gly3 also be added to further improve the water solubility and pharmacokinetic propertie